---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059189"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:58:35.865462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q1 2023 net loss of $18.0M; GSBR-1290 advancing to Phase 2a

## Summary
- Net loss of $18.0M for Q1 2023, compared to $13.1M in Q1 2022; non-cash stock-based comp $2.5M.
- Cash, cash equivalents and short-term investments totaled $240.9M; expected to fund operations through end of 2025.
- R&D expenses $13.1M (up from $8.5M) driven by GLP-1R franchise advancement and stock-based compensation.
- GSBR-1290 protocol amendment submitted to FDA to transition to Phase 2a proof-of-concept study in T2DM and obesity.
- Topline data from Phase 1b MAD and Phase 2a studies of GSBR-1290 expected in second half 2023.

## SEC filing metadata
- accession: 0001104659-23-059189
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/0001104659-23-059189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/tm2315251d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059189
- JSON: https://secwatch.observer/filing/0001104659-23-059189.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059189.txt

## Key facts
- Earnings Releases
  Structure Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $18.0 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $18.0 million
  - Result: reported results
  source text: Net loss totaled $18.0 million for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/0001104659-23-059189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.